Why was Brazil selected as the country for the DSJI clinical trials?
Middle-income and emerging-economy countries, such as Brazil, represent an optimal scenario for launching manufacturing of DSJIs and introducing them into an immunization program. Brazil as a site offers the following advantages: public-sector vaccine manufacturers that have pledged support of the DSJI project, a WHO-recognized national regulatory authority, a strong immunization program, and existing in-country partnerships with PATH. Brazil also has a history of using previous-generation jet injectors in its immunization campaigns and is interested in exploring new developments in the technology class.
